Skip Navigation LinksHome > February 20, 2013 - Volume 27 - Issue 4 > Outcomes after reinitiating antiretroviral therapy in childr...
doi: 10.1097/QAD.0b013e32835c1181
Clinical Science

Outcomes after reinitiating antiretroviral therapy in children randomized to planned treatment interruptions

Bunupuradah, Torsak; Duong, Trinh; Compagnucci, Alexandra; McMaster, Paddy; Bernardi, Stefania; Kanjanavanit, Suparat; Rampon, Osvalda; Faye, Albert; Saïdi, Yacine; Riault, Yoann; De Rossi, Anita; Klein, Nigel; Ananworanich, Jintanat; Gibb, Diana; on behalf of the PENTA 11 Extension Study Group

Collapse Box


Background: Excess risks for death/opportunistic disease in adults randomized to CD4-driven planned treatment interruption (PTI) in the Strategies for Management of Antiretroviral Therapy (SMART) trial remained after antiretroviral therapy (ART) re-initiation. Risks for children following PTI were evaluated in long-term follow-up of children in the PENTA 11 trial.

Methods: Children with HIV RNA below 50 copies/ml and CD4 at least 30% (2–6 years) or at least 500 cells/μl (7–15 years) were randomized to continuous ART (cART) or PTI in PENTA 11 (ISRCTN 36694210). After the end of the trial, all were recommended to resume ART. Data were collected annually and analysed up to the second year of visit.

Results: One hundred and one (51 cART, 50 PTI; median baseline age 9.2 years) children had median overall follow-up 4.6 (range 3.7–5.0) years. During 2-year post-trial period, there were no deaths or new Centers for Disease Control and Prevention (CDC) stage B/C events. Rate of clinical grade of at least two events was similar between PTI and cART [relative risk (RR) 1.03; 95% confidence interval (CI) 0.43, 2.50; P = 0.94]. At 2 years, difference in absolute CD4% between PTI and cART was −1.6% (−4.5%; 1.3%; P = 0.27), and proportions with HIV RNA below 50 copies/ml were 82 versus 86% (P = 0.57), respectively; no differences in growth or fasting lipids were observed. Key predictors of greater CD4% recovery after re-initiating ART were higher CD4% at baseline (P < 0.001) and longer time since ART re-initiation (P < 0.001). During overall follow-up, 4 (8%) PTI versus 5 (10%) CT children switched ART for failure (P = 0.75) and 9 (18%) versus 1 (2%) (P = 0.008) substituted ART for simplification.

Conclusions: No adverse clinical, immunological or virological consequences of PTI were observed 2 years after the end of PENTA 11 trial. Although ART interruption is not generally recommended, it may be an acceptable option for children, particularly when there is high risk of unplanned treatment interruptions.

Copyright © 2013 Wolters Kluwer Health, Inc.


Article Tools


Article Level Metrics

Search for Similar Articles
You may search for similar articles that contain these same keywords or you may modify the keyword list to augment your search.